The OmniVu^™ Lens System

At Atia Vision (a Shifamed portfolio company), we are committed to improving the lives of patients with presbyopia and cataracts by overcoming longstanding limitations in IOL technology. We are focused on the needs of patients who seek premium vision solutions but don’t want to compromise between quality and range of vision. We believe this common trade-off is the reason why the global adoption of presbyopia-correcting IOLs (PC-IOLs) remains low—just 6.3% of total IOL procedures¹—despite the global prevalence of presbyopia and cataracts.

Current approved IOLs either lack accommodative range or split light across focal points. Multifocal and EDOF IOLs tend to impart visual phenomena and blurry zones, where prior attempts at accommodating IOLs fall short on refractive predictability.

Thus, we saw the need for a novel IOL design that could leverage the eye’s natural accommodative mechanism to deliver dynamic, high-quality vision at all distances without inducing visual disturbances. Toward this goal, we developed the OmniVu™ Lens System, a modular, 2-piece IOL designed to engage the eye’s physiologic focusing mechanism to address presbyopia at the time of cataract surgery.

Restoring Youthful Vision

The OmniVu Lens System includes two distinct components: (1) a fluid-filled, shape-changing, biocompatible silicone base that is designed to alter its anterior curvature in response to zonular tension, thereby enabling dynamic shape change and providing “zoom” functionality; and (2) a monofocal optic made from hydrophobic acrylic that docks into the base to provide refractive power. Following routine cataract surgery, the base lens is inserted into the capsular bag and the front optic docks into the base. When provided a near vision stimulus, the eyes’ natural focusing mechanism exerts force on the base. In response, the lens system is designed to move fluid between the base periphery and base center to change its shape and focusing power so that patients achieve functional vision at all distances with monofocal-like side effects (Figure).

Crucially, the OmniVu Lens System is designed to fully fill the capsular bag to preserve the bag’s physiologic shape, stabilize the effective lens position, and minimize posterior capsular opacification.

Clinical Performance

The OmniVu Lens System has been evaluated internationally in both first-in-human and feasibility studies, with over 75 lenses implanted and almost 3 years of follow-up on early cohorts.²

Key clinical findings include UCVA (monocular and binocular) of 20/16 at distance, 20/20 at intermediate, and 20/25 at near vision; no refractive enhancements to date; and no visually-significant PCO and minimal-to-no reports of glare, halos, and starbursts.

In May 2025, we received Investigational Device Exemption (IDE) approval from the U.S. FDA to begin a traditional feasibility clinical study of the OmniVu Lens System.

Platform Potential

With the creation of OmniVu, we aim to break the adoption stalemate patients and surgeons experience in the presbyopia-correction market. Additionally, the lens’ patented, expandable platform can accommodate future enhancements, including toric or light-adjustable optics and drug-delivery reservoirs. We are developing a machine-learning–based algorithm to enhance outcome predictability by correlating biometric data with refractive targets and lens power selection. When combined with promising competitive clinical outcomes, we believe OmniVu Lens System and its future-proof platform design represent the next generation of IOLs.

1. https://eyewire.news/news/market-scope-global-pc-iol-demand-rises-modestly-soars-in-a-few-countries?c4src=article:infinite-scroll.

2. Data on file, Atia Vision, 2025

For more information: https://atiavision.com/#solution

For inquiries, contact Yari Mitchell at yari.mitchell@launchlabpartners.com